More on URGN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+92.8% Growth)
- Ratings (7.7 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

UroGen Pharma (NQ:URGN)
Delayed: 34.22 -0.27 (0.78%)
Prev. Close $34.49  
Open$34.64 
52 Wk High$ 
52 Wk Low$ 
Day High$35.00 
Day Low$34.13 
P/E N/A  
EPS$ 
Volume137,725 

Friends, Peers and Foes (?): ABBV, ARGX, ARWR, BBIO, CGON (more...)

Oct 20, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
Oct 19, 2026 08:00 AM FDA accepts UroGen's NDA for bladder cancer drug UGN-103
Oct 19, 2026 08:00 AM UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Oct 9, 2026 12:57 PM Form 4 UroGen Pharma Ltd. For: Oct 08 Filed by: Degnan Chris
Oct 9, 2026 06:24 AM Form 144 UroGen Pharma Ltd. Filed by: Degnan Chris
Sep 10, 2026 02:43 AM Jefferies Reiterates Buy Rating on UroGen Pharma (URGN)
Sep 4, 2026 08:00 AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2026 08:00 AM UroGen Pharma to Present at Upcoming Investor Conferences
Aug 28, 2026 04:02 PM Form 4 UroGen Pharma Ltd. For: Aug 26 Filed by: Robinson James A. Jr.
Aug 24, 2026 05:03 PM Form 4 UroGen Pharma Ltd. For: Aug 20 Filed by: Schoenberg Mark
View All Articles

Entities mentioned with URGN

View All Entities